Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
- Sponsor
- Asan Medical Center
- Study ID
- NCT01471470
- Phase
- PHASE2
- Status
- Completed
Conditions
- Advanced Gastric Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab — DRUGBevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
Study Details
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
Key Dates
- First listed
- Nov 15, 2011
- Start date
- Jul 31, 2010
- Status verified
- Jan 2020
- Primary completion
- Dec 31, 2017
- Completion
- Jul 31, 2018
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: neoadjuvant
Primary Outcome Measure
R0 resection rate [ Time Frame: Up to 4 weeks after surgery ]
Related Studies
- Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ AdenocarcinomaPHASE1/PHASE2 · Recruiting · BigHat Biosciences, Inc. · Fairfax, Virginia